Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models
Discovery of new drugs for cancer treatment is an expensive and time-consuming process and the percentage of drugs reaching the clinic remains quite low. Drug repositioning refers to the identification and development of new uses for existing drugs and represents an alternative drug development stra...
Guardado en:
| Autores principales: | Rico, María José, Baglioni, María, Bondarenko, Maryna, Laluce, Nahuel Cesatti, Rozados, Viviana R., André, Nicolas, Carré, Manon, Scharovsky, O. Graciela, Márquez, Mauricio Menacho |
|---|---|
| Formato: | article artículo publishedVersion |
| Lenguaje: | Inglés |
| Publicado: |
Rapamycin Press
2018
|
| Materias: | |
| Acceso en línea: | http://hdl.handle.net/2133/11407 http://hdl.handle.net/2133/11407 |
| Aporte de: |
Ejemplares similares
-
Achievements and challenges in the use of metronomics for the treatment of breast cancer
por: Scharovsky, O. Graciela, et al.
Publicado: (2020) -
Repositioning metformin and propranolol for colorectal and triple negative breast cancers treatment
por: Anselmino, L. E., et al.
Publicado: (2022) -
Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients
por: Perroud, Herman A, et al.
Publicado: (2018) -
Clinical response in patients with ovarian cancer treated with metronomic chemotherapy
por: Perroud, Herman A, et al.
Publicado: (2018) -
Metastatic breast cancer patients treated with low-dose metronomic chemotherapy with cyclophosphamide and celecoxib: clinical outcomes and biomarkers of response
por: Perroud, Herman A, et al.
Publicado: (2018)